Spotlight
Video

ARAMIS: Phase 3 trial of ODM-201 for high-risk non-metastatic castration-resistant prostate cancer | Prof Karim Fizazi at Annual Meeting 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, Villejuif, France, discusses the ongoing phase 3 ARAMIS trial, which is evaluating the efficacy and safety of the novel androgen receptor inhibitor, ODM-201, in men with high-risk non-metastatic castration-resistant prostate cancer.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 07/22/15
Added : 4 years ago
Category : Prostate Cancer